Sign in
CompletedPhase 2

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Key facts

Who runs it
VA Office of Research and Development
Where
The Bronx and West Orange, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
36 people enrolled
Started
1 Mar 2021
Ended
24 Aug 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Romosozumab
  • Denosumab
  • Placebo
Record updated
21 September 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Motor-complete or incomplete spinal cord injury (SCI) [all levels of lesion] classified using International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale] as ISNCSCI score A-C
  • Duration of injury >3 years
  • Males (18-65 years old) and females (premenopausal, between the ages of 18 and 55 years old)
  • Areal bone mineral density (aBMD) at the distal femur <1.0 g/cm2 (determined at screening)

Who cannot take part

  • History of prior bone disease (Paget's hyperparathyroidism, etc.)
  • Men with known hypogonadism prior to spinal cord injury (SCI)
  • Anabolic therapy longer than six months duration after spinal cord injury (SCI)
  • Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute spinal cord injury (SCI)
  • Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed)
  • Active and/or history of coronary heart disease or stroke within the past year
  • Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.)
  • Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure)
  • Current diagnosis of cancer or history of cancer
  • Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
  • Long-bone fracture of the leg within the past year
  • Postmenopausal women
  • Chronic alcohol abuse
  • Hypocalcemia
  • Pregnancy
  • Electrical stimulation of the lower extremities
  • Osteosarcoma
  • Life expectancy less than 5 years

Where in United States

  • James J. Peters VA Medical Center, Bronx, NYThe Bronx, United States
  • Kessler Institute for RehabilitationWest Orange, United States

About the trial

What the trial wants to find out

Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD).

Read full original descriptionShow less

The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.

The 3 groups in the trial

  • Romosozumab Treatment (baseline to month 11)Treatment being tested

    Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.

    Treatment: Romosozumab

  • Placebo (baseline to month 12)Placebo, for comparison

    Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.

    Treatment: Placebo

  • Denosumab (month 12 to month 24)Existing treatment, for comparison

    Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).

    Treatment: Denosumab

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
21 September 2026